OraLiva, Inc. is on the cusp of launching an AI-powered cytology “lab-in-a-kit” platform aimed at transforming early oral cancer diagnosis. The system captures cells via a non-invasive brush biopsy, runs them through OraLiva’s proprietary AI engine and compares the sample against a deep clinical dataset to detect early dysplasia or malignancy with high precision.
Why this is important
Oral cancer carries a high mortality rate in the U.S. largely because diagnoses often happen late. OraLiva’s approach enables dental providers—not just specialists—to identify concerning lesions sooner.
By providing near-real-time, multi-parameter cellular analysis (looking at morphology, protein markers, etc.), the test can lead to targeted referrals earlier, better patient prognoses, and fewer unnecessary interventions.
Why NYU?
OraLiva’s technology builds on over a decade of research at NYU College of Dentistry and the McDevitt Lab, which produced the largest oral lesion study to date. The NYU Entrepreneurial Institute, the NYU Innovation Venture Fund and academic partnerships have been instrumental in helping OraLiva translate this scientific foundation into a commercial venture providing both funding and guidance as the company moves toward clinical deployment.
